menu
    • menu
    [{"orgOrder":0,"company":"Newleos Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"NTX-1955","moa":"GABAA-gamma-1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Newleos Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.089999999999999997,"dosageForm":"Oral Capsule","sponsorNew":"Newleos Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"Newleos Therapeutics \/ Goldman Sachs & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Newleos Therapeutics

    Menu

    Newleos Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Newleos Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Newleos Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTX-1955

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $93.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Newleos Raises $93.5M Series A to Advance Neuropsychiatric Treatments

                            Details : The financing aims to fund the clinical development of Newleos’ lead program, RO7308480 (NTX-1955), is a first-in-class GABAA-γ1 selective PAM designed to treat anxiety disorders.

                            Product Name : RO7308480

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 13, 2025

                            Lead Product(s) : NTX-1955

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $93.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth